Valsartan

• 

  Subject Areas on Research

  • Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. 
  • An outcome model approach to transporting a randomized controlled trial results to a target population. 
  • Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. 
  • Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. 
  • Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. 
  • Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial. 
  • Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. 
  • Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. 
  • Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. 
  • Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. 
  • Blockade of angiotensin II type 2 receptor by PD123319 inhibits osteogenic differentiation of human mesenchymal stem cells via inhibition of extracellular signal-regulated kinase signaling. 
  • Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions. 
  • Cardiac protection: evolving role of angiotensin receptor blockers. 
  • Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. 
  • Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. 
  • Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. 
  • Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction. 
  • Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. 
  • Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. 
  • Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). 
  • Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. 
  • Determining the most appropriate components for a composite clinical trial outcome. 
  • Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. 
  • Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). 
  • Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. 
  • Effect of nateglinide on the incidence of diabetes and cardiovascular events. 
  • Effect of valsartan on the incidence of diabetes and cardiovascular events. 
  • Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. 
  • Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. 
  • Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. 
  • Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial. 
  • Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry. 
  • Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). 
  • From Theory to Practice: The Use of Real-World Data to Evaluate New Heart Failure Therapies. 
  • Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. 
  • Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • Heterogeneity of health status treatment response with sacubitril/valsartan: insights from the CHAMP-HF registry. 
  • High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. 
  • Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. 
  • Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). 
  • Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. 
  • Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. 
  • In HF with LVEF ≤ 42.5%, sacubitril-valsartan vs RAS inhibitors reduced a composite of CV death or HF hospitalization. 
  • In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time. 
  • Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. 
  • Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. 
  • International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. 
  • Left ventricular assessment in myocardial infarction: the VALIANT registry. 
  • Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. 
  • Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. 
  • Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction. 
  • Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. 
  • Mechanisms and Models in Heart Failure: A Translational Approach. 
  • Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. 
  • Medications Are Important for Sudden Cardiac Death Prevention But So Is the Implantable Cardioverter-Defibrillator. 
  • Meet Me in the Middle: Lessons From the Cardiorenal Advisory Committee for Sacubitril/Valsartan in HFpEF. 
  • Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. 
  • Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). 
  • Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • PROVIDE-HF primary results: Patient-Reported Outcomes inVestigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. 
  • Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. 
  • Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. 
  • Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. 
  • Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. 
  • Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. 
  • Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. 
  • Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. 
  • Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. 
  • Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study. 
  • Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. 
  • Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. 
  • Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. 
  • Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. 
  • Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. 
  • Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. 
  • Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. 
  • Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. 
  • Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. 
  • Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. 
  • Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. 
  • Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. 
  • Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. 
  • Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. 
  • Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. 
  • Sacubitril/Valsartan Therapy for AF and HFpEF: Is the Glass Half Empty or Half Full? 
  • Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. 
  • Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure). 
  • Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. 
  • Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations? 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The Use of Sacubitril/Valsartan for Hospitalized Heart Failure-Why Do We Care About Cost and Value? 
  • The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Therapeutic implications of high-dose angiotensin receptor blocker monotherapy in mild-to-moderate hypertensive patients. 
  • Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). 
  • VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. 
  • Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. 
  • Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. 
  • Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. 
  • Valsartan, captopril, or both in myocardial infarction. 
  • Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial.